R&D

CureVac grabs a $29.5M round to fuel its mRNA development efforts

Ingmar Hoerr

Ingmar Hoerr, CureVac CEO

CureVac, the German mRNA biotech, has added a couple of new investors to the mix who are chipping $29.5 million into the operation as it nears a critical juncture on the R&D side of the business.

The Tübingen-based biotech, which has been primarily backed by German billionaire Dietmar Hopp along with additional funding from Bill Gates’ foundation, says that Baden- Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte (via the LBBW Asset Management Investmentgesellschaft mbH, Stuttgart) and Landeskreditbank Baden-Württemberg added the funds.

So far, CureVac has raised about $360 million, including its latest $110 million mega-round last fall. For just about any biotech, that would be a considerable amount — except for anyone looking to lead in mRNA.

The mRNA space has been dominated by Moderna, which has a raised a mountain of cash, $1.9 billion to date, to build up its manufacturing and field a slate of early-stage clinical products, determined to build a company and a pipeline ahead of the first round of mid-stage trial results.

CureVac, which is partnered with Boehringer Ingelheim and others, has taken a somewhat more traditional path. It has a 6-antigen cancer vaccine that should deliver mid-stage data on prostate cancer in early 2017, which will go a long way toward convincing skeptics they were either right or wrong about this company. And that makes it the most advanced mRNA company on either side of the Atlantic.

I talked with CureVac execs at BIO-Europe this week. They tell me that the company has 270 staffers and has been developing its own manufacturing operations as well as it gears up to head into late-stage development efforts. There’s a lot riding on the upcoming data.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->